Gary Rothbard, MD, MS

Researchers found data that showed patients who have or who are injecting drugs would benefit from treatment for HCV with direct-acting antivirals.

At centers in Asia, Europe, and the Americas, investigators conducted a randomized controlled trial of patients with chronic hepatitis B virus infection to assess the long-term effects of entecavir.

Researchers found data that showed entecavir is safe in the treatment of hepatitis B virus in patients who are undergoing hemodialysis.

Researchers found data that showed early initiation of antiviral therapy with lamivudine in infants with hepatitis B caused a rapid loss of HBsAg.

Investigators found that young age, high HCV viral load, and HCV/HIV co-infection were the factors associated with an increased transmission risk.

In San Francisco, California, researchers found data that showed it was feasible to recruit patients who inject drugs for treatment of hepatitis C with ledipasvir-sofosbuvir for 8 weeks.

Study showed that pamidronate might contribute to clinical improvement and improvement of radiologic outcome in chronic nonbacterial osteomyelitis, however, relapses were frequent.

Patients with rheumatoid arthritis with chronic hepatitis B virus infection demonstrated greater radiographic progression and poorer clinical response at 1 year.